ACRX insider filings
ACELRX PHARMACEUTICALS INC — 50 most recent insider filings (SEC Forms 3/4/5) from EDGAR, normalized by FilingPulse. Latest filing: 2023-12-14. Screen ACRX transaction legs live →
Insider transaction summary — last 90 days
No insider filings (Forms 3/4/5) for ACRX between 2026-08-23 and 2026-11-21. The table below lists the most recent filings on record.
Recent insider filings — ACELRX PHARMACEUTICALS INC
| Filed | Form | Insider | Reported transactions | Source |
|---|---|---|---|---|
| 2023-12-14 | 4 | Angotti Vincent J. — Chief Executive Officer, Director | Purchase (P): 10,000 @ $0.73 | EDGAR |
| 2023-12-13 | 4 | Afable Richard — Director | Grant/award (A): 581 @ $0 · Grant/award (A): 3,487 (derivative) @ $0 | EDGAR |
| 2023-12-13 | 4 | Bozilenko Marina — Director | Grant/award (A): 581 @ $0 · Grant/award (A): 3,487 (derivative) @ $0 | EDGAR |
| 2023-12-13 | 4 | Rosen Howard B — Director | Grant/award (A): 581 @ $0 · Grant/award (A): 3,487 (derivative) @ $0 | EDGAR |
| 2023-12-13 | 4 | ADAMS ADRIAN — Director | Grant/award (A): 581 @ $0 · Grant/award (A): 3,487 (derivative) @ $0 | EDGAR |
| 2023-12-13 | 4 | Broadfoot Jill Marie — Director | Grant/award (A): 581 @ $0 · Grant/award (A): 3,487 (derivative) @ $0 | EDGAR |
| 2023-12-13 | 4 | WAN MARK A — Director | Grant/award (A): 581 @ $0 · Grant/award (A): 3,487 (derivative) @ $0 | EDGAR |
| 2023-12-13 | 4 | HOFFMAN STEPHEN J — Director | Grant/award (A): 581 @ $0 · Grant/award (A): 3,487 (derivative) @ $0 | EDGAR |
| 2023-09-11 | 4 | Angotti Vincent J. — Chief Executive Officer, Director | Purchase (P): 10,000 @ $0.80 | EDGAR |
| 2023-08-25 | 4 | Palmer Pamela P — Chief Medical Officer, Director | Sale (S): 9,514 @ $1.17 · Sale (S): 7,442 @ $1.09 | EDGAR |
| 2023-03-06 | 4 | Palmer Pamela P — Chief Medical Officer, Director | Tax withholding (F): 570 @ $1.31 | EDGAR |
| 2023-03-06 | 4 | ASADORIAN RAFFI — Chief Financial Officer | Tax withholding (F): 510 @ $1.31 | EDGAR |
| 2023-03-06 | 4 | Angotti Vincent J. — Chief Executive Officer, Director | Tax withholding (F): 1,703 @ $1.31 | EDGAR |
| 2023-03-06 | 4 | Dasu Badri N — Chief Engineering Officer | Tax withholding (F): 398 @ $1.31 | EDGAR |
| 2023-02-14 | 4 | Palmer Pamela P — Chief Medical Officer, Director | Grant/award (A): 6,125 @ $0 · Tax withholding (F): 1,017 @ $1.68 · Grant/award (A): 36,750 (derivative) @ $0 | EDGAR |
| 2023-02-14 | 4 | ASADORIAN RAFFI — Chief Financial Officer | Grant/award (A): 5,875 @ $0 · Tax withholding (F): 873 @ $1.68 · Grant/award (A): 35,250 (derivative) @ $0 | EDGAR |
| 2023-02-14 | 4 | Angotti Vincent J. — Chief Executive Officer, Director | Grant/award (A): 19,500 @ $0 · Tax withholding (F): 3,321 @ $1.68 · Grant/award (A): 117,000 (derivative) @ $0 | EDGAR |
| 2023-02-14 | 4 | Dasu Badri N — Chief Engineering Officer | Grant/award (A): 4,875 @ $0 · Tax withholding (F): 776 @ $1.68 · Grant/award (A): 29,250 (derivative) @ $0 | EDGAR |
| 2023-02-08 | 4 | ASADORIAN RAFFI — Chief Financial Officer | Tax withholding (F): 617 @ $2.02 | EDGAR |
| 2023-02-08 | 4 | Palmer Pamela P — Chief Medical Officer, Director | Tax withholding (F): 681 @ $2.02 | EDGAR |
| 2023-02-08 | 4 | Angotti Vincent J. — Chief Executive Officer, Director | Tax withholding (F): 1,982 @ $2.02 | EDGAR |
| 2023-02-08 | 4 | Dasu Badri N — Chief Engineering Officer | Tax withholding (F): 458 @ $2.02 | EDGAR |
| 2022-07-15 | 4 | Bozilenko Marina — Director | Grant/award (A): 15,500 @ $0 · Grant/award (A): 31,000 (derivative) @ $0 | EDGAR |
| 2022-07-15 | 4 | Afable Richard — Director | Grant/award (A): 15,500 @ $0 · Grant/award (A): 31,000 (derivative) @ $0 | EDGAR |
| 2022-07-15 | 4 | Rosen Howard B — Director | Grant/award (A): 15,500 @ $0 · Grant/award (A): 31,000 (derivative) @ $0 | EDGAR |
| 2022-07-15 | 4 | Broadfoot Jill Marie — Director | Grant/award (A): 15,500 @ $0 · Grant/award (A): 31,000 (derivative) @ $0 | EDGAR |
| 2022-07-15 | 4 | ADAMS ADRIAN — Director | Grant/award (A): 15,500 @ $0 · Grant/award (A): 31,000 (derivative) @ $0 | EDGAR |
| 2022-07-15 | 4 | WAN MARK A — Director | Grant/award (A): 15,500 @ $0 · Grant/award (A): 31,000 (derivative) @ $0 | EDGAR |
| 2022-07-15 | 4 | HOFFMAN STEPHEN J — Director | Grant/award (A): 15,500 @ $0 · Grant/award (A): 31,000 (derivative) @ $0 | EDGAR |
| 2022-06-08 | 4 | Angotti Vincent J. — Chief Executive Officer, Director | Purchase (P): 46,400 @ $0.22 | EDGAR |
| 2022-03-04 | 4 | Palmer Pamela P — Chief Medical Officer, Director | Tax withholding (F): 7,923 @ $0.41 | EDGAR |
| 2022-03-04 | 4 | ASADORIAN RAFFI — Chief Financial Officer | Tax withholding (F): 7,923 @ $0.41 | EDGAR |
| 2022-03-04 | 4 | Angotti Vincent J. — Chief Executive Officer, Director | Tax withholding (F): 23,051 @ $0.41 | EDGAR |
| 2022-03-04 | 4 | Dasu Badri N — Chief Engineering Officer | Tax withholding (F): 5,612 @ $0.41 | EDGAR |
| 2022-02-14 | 4 | Palmer Pamela P — Chief Medical Officer, Director | Grant/award (A): 122,500 @ $0 · Tax withholding (F): 7,927 @ $0.40 · Grant/award (A): 245,000 (derivative) @ $0 | EDGAR |
| 2022-02-14 | 4 | ASADORIAN RAFFI — Chief Financial Officer | Grant/award (A): 117,500 @ $0 · Tax withholding (F): 7,927 @ $0.40 · Grant/award (A): 235,000 (derivative) @ $0 | EDGAR |
| 2022-02-14 | 4 | Angotti Vincent J. — Chief Executive Officer, Director | Grant/award (A): 390,000 @ $0 · Tax withholding (F): 23,058 @ $0.40 · Grant/award (A): 780,000 (derivative) @ $0 | EDGAR |
| 2022-02-14 | 4 | Dasu Badri N — Chief Engineering Officer | Grant/award (A): 97,500 @ $0 · Tax withholding (F): 5,615 @ $0.40 · Grant/award (A): 195,000 (derivative) @ $0 | EDGAR |
| 2022-02-07 | 4 | Palmer Pamela P — Chief Medical Officer, Director | Tax withholding (F): 9,391 @ $0.43 | EDGAR |
| 2022-02-07 | 4 | ASADORIAN RAFFI — Chief Financial Officer | Tax withholding (F): 9,391 @ $0.43 | EDGAR |
| 2022-02-07 | 4 | Angotti Vincent J. — Chief Executive Officer, Director | Tax withholding (F): 27,318 @ $0.43 | EDGAR |
| 2022-02-07 | 4 | Dasu Badri N — Chief Engineering Officer | Tax withholding (F): 6,830 @ $0.43 | EDGAR |
| 2021-11-23 | 4 | Broadfoot Jill Marie — Director | Grant/award (A): 15,000 @ $0 · Grant/award (A): 30,000 (derivative) @ $0 | EDGAR |
| 2021-06-17 | 4 | Afable Richard — Director | Grant/award (A): 10,000 @ $0 · Grant/award (A): 20,000 (derivative) @ $0 | EDGAR |
| 2021-06-17 | 4 | Bozilenko Marina — Director | Grant/award (A): 10,000 @ $0 · Grant/award (A): 20,000 (derivative) @ $0 | EDGAR |
| 2021-06-17 | 4 | Rosen Howard B — Director | Grant/award (A): 10,000 @ $0 · Grant/award (A): 20,000 (derivative) @ $0 | EDGAR |
| 2021-06-17 | 4 | ADAMS ADRIAN — Director | Grant/award (A): 10,000 @ $0 · Grant/award (A): 20,000 (derivative) @ $0 | EDGAR |
| 2021-06-17 | 4 | WAN MARK A — Director | Grant/award (A): 10,000 @ $0 · Grant/award (A): 20,000 (derivative) @ $0 | EDGAR |
| 2021-06-17 | 4 | EDWARDS MARK G — Director | Grant/award (A): 10,000 @ $0 · Grant/award (A): 20,000 (derivative) @ $0 | EDGAR |
| 2021-06-17 | 4 | HOFFMAN STEPHEN J — Director | Grant/award (A): 10,000 @ $0 · Grant/award (A): 20,000 (derivative) @ $0 | EDGAR |
Recent 8-K events — ACELRX PHARMACEUTICALS INC
Items classified from EDGAR index headers. Browse recent 8-K filings market-wide, by item code →
| Filed | Form | Items reported | Source |
|---|---|---|---|
| 2026-11-12 | 8-K | 2.02 — Results of Operations and Financial Condition 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-08-12 | 8-K | 2.02 — Results of Operations and Financial Condition 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-06-23 | 8-K | 5.02 — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers 5.07 — Submission of Matters to a Vote of Security Holders 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-05-13 | 8-K | 2.02 — Results of Operations and Financial Condition 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-03-23 | 8-K | 2.02 — Results of Operations and Financial Condition 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-03-16 | 8-K | 3.02 — Unregistered Sales of Equity Securities | EDGAR |
| 2026-03-13 | 8-K | 3.01 — Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing | EDGAR |
| 2025-11-12 | 8-K | 2.02 — Results of Operations and Financial Condition 9.01 — Financial Statements and Exhibits | EDGAR |
| 2025-10-24 | 8-K | 5.02 — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers 5.07 — Submission of Matters to a Vote of Security Holders 9.01 — Financial Statements and Exhibits | EDGAR |
| 2025-10-22 | 8-K | 3.02 — Unregistered Sales of Equity Securities 8.01 — Other Events | EDGAR |
Need this as JSON?
GET https://api.filingpulse.io/v1/insider-trades?ticker=ACRX returns every filing on this page — normalized, with footnotes and derivative legs — and webhooks push new ones to you in seconds. Get a free API key → · API docs